Michelle Nunes Caravaglio, MD
Epilepsy · Jacksonville Beach, FLNPI 1992245450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for epilepsy clinicians in FL, where the typical reported total is $6,512.
Across 165 payments — averaging $27.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$542
- Argenx US, Inc.$413
- SK Life Science, Inc.$378
- UCB, Inc.$342
- Novartis$284
- AstraZeneca$238
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,48199%
- Education$361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $542 |
| Argenx US, Inc. | 15 | $413 |
| SK Life Science, Inc. | 7 | $378 |
| UCB, Inc. | 12 | $342 |
| Novartis | 11 | $284 |
| AstraZeneca(2 entities) | 10 | $238 |
| Amgen(2 entities) | 4 | $206 |
| Lundbeck LLC | 11 | $204 |
| Neurelis, Inc. | 4 | $196 |
| Genentech USA, Inc. | 7 | $176 |
| Lilly USA, LLC | 8 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $167 |
| Greenwich Biosciences, Inc. | 1 | $127 |
| TG Therapeutics, Inc. | 1 | $126 |
| Livanova USA, Inc. | 1 | $126 |
| Teva Pharmaceuticals USA, Inc. | 5 | $113 |
| Pfizer | 5 | $111 |
| Tanabe Pharma America, Inc. | 4 | $94 |
| Biogen | 4 | $91 |
| Mallinckrodt Hospital Products Inc. | 4 | $86 |
| EMD Serono, Inc. | 4 | $77 |
| Catalyst Pharmaceuticals, Inc. | 2 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $63 |
| Sanofi | 3 | $52 |
| Merz North America, Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$127
- BRIUMVI$126
- VNS Therapy$126
- UPLIZNA$125
- XCOPRI$122
- VALTOCO$112
- Cenobamate$111
- Fintepla$103
How this compares
$4,517 in reported general payments places this provider in the 40th percentile of 23 epilepsy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AptiomEslicarbazepine Acetate | 13 | $33,216 |
| XcopriCenobamate | 25 | $29,069 |
| Nurtec OdtRimegepant Sulfate | 14 | $26,352 |
| BriviactBrivaracetam | 13 | $18,083 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $16,457 |
| QuliptaAtogepant | 15 | $16,273 |
| NayzilamMidazolam | 18 | $12,056 |
| Levetiracetam ErLevetiracetam | 85 | $4,273 |
| Lacosamide | 61 | $2,840 |
| Levetiracetam | 51 | $1,654 |
| Divalproex Sodium ErDivalproex Sodium | 31 | $1,351 |
| Oxcarbazepine | 11 | $1,036 |
| Lamotrigine ErLamotrigine | 11 | $1,015 |
| Memantine Hcl | 28 | $806 |
| Memantine Hcl ErMemantine Hcl | 11 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam | $342 | $30,13831 claims |
| SK Life Science, Inc.Xcopri | $378 | $29,06925 claims |
| PfizerNurtec Odt | $111 | $26,35214 claims |
| AbbVieQulipta | $542 | $16,27315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 23 epilepsy providers in Florida.
Other epilepsy in Jacksonville Beach
- Brian CostellBoca Raton$469K
- Andrew LermanMiami$249K
- Alberto Pinzon ArdilaMiami$144K
- Jaivir RathoreOrlando$38K
- Dipali NemadeOrlando$38K
- Mohamed NasserWeston$28K
- William TatumJacksonville$28K
- Brin FreundJacksonville$18K
- Miguel Melo-BicchiMiami$15K
- Claudio OsorioTampa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.